LAS VEGAS--(BUSINESS WIRE)--Speaking today at the Targets and Strategies in Drug Discovery Summit in Las Vegas, Dr. Gady Cojocaru, Head of Target Discovery at Compugen Ltd. (NASDAQ: CGEN), presented Compugen’s prediction based discovery strategy by focusing on two of the methodologies being utilized by the Company for the identification of novel targets for monoclonal antibody (mAb) cancer therapy. Also included in the presentation was the disclosure of CGEN-15022 and CGEN-15092, two of the B7/CD28-like proteins discovered by the Company that have shown potential in initial validation studies for this therapeutic use.
